{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:43:57Z","timestamp":1785368637427,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The influence of a previous Urolift treatment on the outcomes of prostate Aquablation is still controversial. This retrospective cohort study aimed to evaluate the perioperative outcomes, efficacy, feasibility, and safety of Aquablation after previous Urolift treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The charts of patients with benign prostate hyperplasia (BPH) complicated by storage and voiding symptoms, who were previously treated with Urolift followed by Aquablation between January 2022 and July 2024, were retrospectively reviewed and analyzed for changes in International Prostate Symptom Score (IPSS), maximum urinary flow rates (Qmax), and postvoid residual volume (PVR) from baseline (pre-Aquablation) to the mean of three months postoperatively. Day-case surgery was performed in 75% of the cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 40 patients with a mean age of 68 (SD\u2009\u00b1\u20098.91) years with moderately enlarged prostates (mean volume 81.56 mL, (SD\u2009\u00b1\u200925.32), and median PSA 3.2 ng\/dL). Five patients were presented initially with an indwelling Foley catheter, so their data were not included in the statistical analysis. After Aquablation, the mean IPSS improved from 24.7 (SD\u2009\u00b1\u20097.63) at baseline to 9.8 (SD\u2009\u00b1\u20092.55) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), the mean Qmax increased from 9.6mL\/sec (SD\u2009\u00b1\u20095.76) at baseline to 20.8mL\/sec (SD\u2009\u00b1\u20096.28) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and the mean PVR decreased from 143mL (SD\u2009\u00b1\u2009104.89) at baseline to 36mL (SD\u2009\u00b1\u200930.63 ) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The hospital stay for patients admitted ranged from 1 to 2 days. Moreover, there were no major intraoperative difficulties removing dislodged Urolift clips with a loop resectoscope at the end of the procedure, while non-dislodged clips were left in situ. None of the patients had postoperative bleeding that required hospital admission or blood transfusion following discharge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on these results, prostate Aquablation appeared to be an effective, safe, feasible, and reliable surgical procedure for BPH patients who have had previous Urolift treatment. Further prospective and larger scale studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05897-7","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:41:18Z","timestamp":1756896078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy, feasibility, and safety of aquablation after previous urolift treatment of lower urinary tract symptoms secondary to benign prostate hyperplasia: a retrospective cohort study"],"prefix":"10.1007","volume":"43","author":[{"given":"Hashem","family":"Darwazeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng Lim","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"issue":"2","key":"5897_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prnil.2017.01.007","volume":"5","author":"D Christidis","year":"2017","unstructured":"Christidis D, McGrath S, Perera M et al (2017) Minimally invasive surgical therapies for benign prostatic hypertrophy: the rise in minimally invasive surgical therapies. Prostate Int 5(2):41\u201346. https:\/\/doi.org\/10.1016\/j.prnil.2017.01.007","journal-title":"Prostate Int"},{"key":"5897_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.urology.2016.05.003","volume":"97","author":"P Jones","year":"2016","unstructured":"Jones P, Rajkumar G, Rai BP et al (2016) Medium-term outcomes of urolift (Minimum 12 months follow-up): evidence from a systematic review. Urology 97:20\u201324. https:\/\/doi.org\/10.1016\/j.urology.2016.05.003","journal-title":"Urology"},{"key":"5897_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00345-025-05795-y","volume":"43","author":"S Moretto","year":"2025","unstructured":"Moretto S, Wirtzfeld N, Doizi S et al (2025) Local anesthesia for UroLift\u00ae: a systematic review of the literature. World J Urol 43:435. https:\/\/doi.org\/10.1007\/s00345-025-05795-y","journal-title":"World J Urol"},{"issue":"3","key":"5897_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.juro.2018.05.048","volume":"200","author":"HE Foster","year":"2018","unstructured":"Foster HE, Barry MJ, Dahm P et al (2018) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol 200(3):612\u2013619. https:\/\/doi.org\/10.1016\/j.juro.2018.05.048","journal-title":"J Urol"},{"key":"5897_CR5","doi-asserted-by":"publisher","unstructured":"-Nickel JC, Aaron L, Barkin J et al (2018) Canadian urological association guideline on male lower urinary tract symptoms\/benign prostatic hyperplasia (MLUTS\/BPH): 2018 update. Can Urol Assoc J 12(10). https:\/\/doi.org\/10.5489\/cuaj.5616","DOI":"10.5489\/cuaj.5616"},{"issue":"6","key":"5897_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of nonneurogenic male lower urinary uract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099\u20131109. https:\/\/doi.org\/10.1016\/j.eururo.2014.12.038","journal-title":"Eur Urol"},{"issue":"1","key":"5897_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bju.14917","volume":"125","author":"D Nguyen","year":"2019","unstructured":"Nguyen D, Barber N, Bidair M et al (2019) Waterjet ablation therapy for endoscopic resection of prostate tissue trial (WATER) vs WATER II: comparing aquablation therapy for benign prostatic hyperplasia in 30\u201380 and 80\u2013150 mL prostates. BJU Int 125(1):112\u2013122. https:\/\/doi.org\/10.1111\/bju.14917","journal-title":"BJU Int"},{"issue":"1","key":"5897_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/end.2014.0304","volume":"29","author":"K Faber","year":"2014","unstructured":"-Faber K, De Abreu ALC, Ramos P et al (2014) Image-Guided Robot-Assisted prostate ablation using water Jet-Hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 29(1):63\u201369. https:\/\/doi.org\/10.1089\/end.2014.0304","journal-title":"J Endourol"},{"key":"5897_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2024.08.006","author":"KC Zorn","year":"2024","unstructured":"Zorn KC, Chakraborty A, Chughtai B et al (2024) Safety and efficacy of same day discharge for men undergoing contemporary Robotic-Assisted aquablation prostate surgery in an ambulatory surgery center setting \u2013 first global experience. Urology. https:\/\/doi.org\/10.1016\/j.urology.2024.08.006","journal-title":"Urology"},{"issue":"1","key":"5897_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1557988315616676","volume":"11","author":"E Shortridge","year":"2015","unstructured":"Shortridge E, Donatucci C, Donga P et al (2015) Adherence and persistence patterns in medication use among men with lower urinary tract symptoms\/benign prostatic hyperplasia. Am J Mens Health 11(1):164\u2013169. https:\/\/doi.org\/10.1177\/1557988315616676","journal-title":"Am J Mens Health"},{"issue":"6","key":"5897_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.urology.2015.07.019","volume":"86","author":"SA -Strope","year":"2015","unstructured":"-Strope SA, Vetter J, Elliott S et al (2015) Use of medical therapy and success of laser surgery and transurethral resection of the prostate for benign prostatic hyperplasia. Urology 86(6):1115\u20131122. https:\/\/doi.org\/10.1016\/j.urology.2015.07.019","journal-title":"Urology"},{"issue":"3","key":"5897_CR12","first-page":"8802","volume":"24","author":"C Roehrborn","year":"2017","unstructured":"Roehrborn C, Barkin J, Gange SN et al (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. Study. 2017. Can J Urol 24(3):8802\u20138813","journal-title":"Can J Urol"},{"issue":"5","key":"5897_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.juro.2017.12.065","volume":"199","author":"P Gilling","year":"2018","unstructured":"Gilling P, Barber N, Bidair M et al (2018) WATER: A Double-Blind, randomized, controlled trial of aquablation \u00ae vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 199(5):1252\u20131261. https:\/\/doi.org\/10.1016\/j.juro.2017.12.065","journal-title":"J Urol"},{"issue":"1","key":"5897_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/end.2024.0370","volume":"39","author":"DE -Sanchez","year":"2025","unstructured":"Sanchez DE, Ghoreifi A, Storino Ramacciotti L, Cai J, Maas M, Venkat A et al (2025) The safety and feasibility of aquablation in patients with previous surgery for benign prostatic hyperplasia. J Endourol 39(1):50\u201355. https:\/\/doi.org\/10.1089\/end.2024.0370","journal-title":"J Endourol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05897-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05897-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:51:29Z","timestamp":1767966689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05897-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5897"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05897-7","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"535"}}